The ING1 Knockout HT29 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population derived from the human colorectal adenocarcinoma cell line HT29, targeting the tumor suppressor gene ING1. This loss-of-function model allows for the investigation of ING1-dependent regulatory networks in intestinal epithelial cells. The polyclonal nature of the knockout population maintains genetic heterogeneity, simulating natural tumor heterogeneity and enabling robust functional studies without clonal selection bias. Engineered using CRISPR/Cas9-mediated gene disruption, these cells provide a reliable and efficient tool for dissecting ING1??s role in cancer biology.
The HT29 host cell line is an adherent epithelial cell line isolated from a 44-year-old female with colorectal adenocarcinoma. HT29 cells are widely used as a preclinical model for colorectal cancer research due to their capacity to recapitulate key aspects of intestinal epithelial cell biology, including differentiation potential and tumorigenic properties. The parental HT29 cells harbor mutant TP53 and APC, among other oncogenic alterations, making them particularly relevant for studying the p53 signaling pathway and tumor suppressor interactions in a disease-relevant genetic background.
ING1 functions as a type II tumor suppressor that physically interacts with p53 and histone acetyltransferase complexes, including PCAF, p300, and HDAC1, to enhance p53-dependent transcription of genes governing cell cycle arrest and apoptosis. ING1 is upregulated in response to DNA damage and stress stimuli, acting downstream of p53, E2F1, and TGF-beta signaling. It promotes expression of CDKN1A (p21) and BAX while repressing cyclins and CDKs, thereby enforcing G1/S checkpoint control and apoptotic programs. Additionally, ING1 associates with chromatin remodeling factors such as BRG1, SAP30, and mSin3A to modulate local chromatin structure at target promoters, facilitating p53-mediated transcriptional responses. Loss of ING1 disrupts these interactions, attenuating p53 activity and impairing DNA damage-induced cell fate decisions.
In the context of HT29 colorectal adenocarcinoma cells, ING1 knockout models the inactivation of this tumor suppressor frequently observed in colorectal, gastric, and breast cancers. The loss of ING1 compromises p53-dependent cell cycle arrest and apoptosis, contributing to genomic instability and unchecked proliferation despite the presence of wild-type p53 regulatory mechanisms. This model enables precise dissection of ING1??s role in DNA damage response and its interplay with p53, p21, BAX, and other downstream effectors within a colorectal cancer background. Therefore, it serves as a relevant system for exploring tumorigenic mechanisms and therapeutic vulnerabilities associated with ING1 deficiency.
The ING1 Knockout HT29 Polyclonal Cells are suitable for a wide range of applications, including colorectal cancer research, p53 pathway analysis, drug resistance studies, and DNA damage response investigations. Typical assays include western blotting to assess ING1, p53, and p21 protein levels; RT-qPCR for gene expression profiling; MTT cell viability and Annexin V apoptosis assays; flow cytometric cell cycle analysis; colony formation assays; and xenograft tumor growth studies. Co-immunoprecipitation and ChIP-qPCR can further elucidate ING1??s protein interactions and chromatin binding dynamics. For technical inquiries or batch-specific information, please contact Ascent Research.
